Advanced Search
MyIDEAS: Login

I Farmaci Oncologici in Italia: innovazione e sostenibilità economica

Contents:

Author Info

  • Fabio Pammolli

    ()
    (IMT Lucca Institute for Advanced Studies and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    ()
    (IMT Lucca Institute for Advanced Studies and and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

  • Nicola Carmine Salerno

    ()
    (EIOPA - European Insurance and Occupational Pensions Authority)

Abstract

I farmaci innovativi ad alto costo ci fanno toccare con mano quali potranno essere i dilemmi della sanità futura se non si completano le riforme della governance di questo capitolo complesso della spesa pubblica (non solo federalismo, ma sistemi contabili e di reporting, schemi di compartecipazione al costo, screening delle prassi terapeutiche per sollecitare best practice, etc.). Quel trade-off crudo che abbiamo di fronte, tra sostenibilità della spesa e domanda di prestazioni da parte dei cittadini, è, per i farmaci ad alto costo, già una realtà vissuta in tutti gli ospedali. Nella prima parte del rapporto Pammolli, Riccaboni e Salerno descrivono le caratteristiche del comparto, fornendone le grandezze principali attuali e prospettiche, anche in chiave di comparazione internazionale. Nella seconda parte, gli autori approfondiscono il quadro normativo-regolatorio che attualmente presiede alla governance dei farmaci oncologici in Italia. Ne emerge un sistema con ombre e approssimazioni, con impostazioni diverse e spesso incompatibili tra Aifa e Regioni, tra Regione e Regione, addirittura tra Als e Ospedali di una stessa Regione. Un assetto poco trasparente e certo non pronto a governare in maniera positiva e programmatica la forbice tra risorse spendibili e necessità e urgenza delle terapie. Nella parte conclusiva del rapporto si avanzano alcune proposte di policy, distinguendo tra quelle attuabili in tempi brevi e quelle per le quali sono necessari tempi di attuazione più lunghi. Le due tipologie di intervento andrebbero avviate il prima possibile e auspicabilmente condotte in parallelo.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.cermlab.it/wp-content/uploads/cerm/wp/wpcerm-2012-02.pdf
File Function: First version, 2012
Download Restriction: no

Bibliographic Info

Paper provided by Competitività Regole Mecati (CERM) in its series Working Papers with number 02-2012.

as in new window
Length: 71 pages
Date of creation: Jun 2012
Date of revision:
Handle: RePEc:ern:wpaper:02-2012

Contact details of provider:
Postal: Via Fiorentina, 1, 53100 Siena
Phone: +39 3488120691
Email:
Web page: http://www.cermlab.it/
More information through EDIRC

Related research

Keywords: farmaci oncologici; sanità; sostenibilità;

Find related papers by JEL classification:

References

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
as in new window
  1. Angus Deaton, 2001. "Health, Inequality, and Economic Development," NBER Working Papers 8318, National Bureau of Economic Research, Inc.
  2. David M. Cutler & Angus S. Deaton & Adriana Lleras-Muney, 2006. "The Determinants of Mortality," NBER Working Papers 11963, National Bureau of Economic Research, Inc.
  3. Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
  4. Sergey V. Buldyrev & Jakub Growiec & Fabio Pammolli & Massimo Riccaboni & H. Eugene Stanley, 2007. "The Growth of Business Firms: Facts and Theory," Journal of the European Economic Association, MIT Press, vol. 5(2-3), pages 574-584, 04-05.
  5. Stefano Capri & Rossella Levaggi, 2010. "Shifting the risk in pricing and reimbursement schemes. A new model of risk-sharing agreements for innovative drugs," LIUC Papers in Economics 234, Cattaneo University (LIUC).
  6. Adrian Towse & Louis P. Garrison, 2010. "Can't Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products," PharmacoEconomics, Springer Healthcare | Adis, vol. 28(2), pages 93-102.
  7. Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
  8. Fabio Pammolli & Massimo Riccaboni & Laura Magazzini, 2010. "The productivity crisis in pharmaceutical R&D," Working Papers 06/2010, University of Verona, Department of Economics.
Full references (including those not matched with items on IDEAS)

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:02-2012. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.